{"id":"beclabuvir","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Potassium voltage-gated channel subfamily H member 2","category":"target"},{"label":"KCNH2","category":"gene"},{"label":"J05AP58","category":"atc"},{"label":"Active","category":"status"},{"label":"Chronic hepatitis C","category":"indication"},{"label":"Bristol-Myers Squibb","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"company":"Bristol-Myers Squibb","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BECLABUVIR","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:16:47.529619+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:17:04.068057+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:16:53.185038+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BECLABUVIR","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:16:53.578527+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4739903/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:16:54.491097+00:00"}},"allNames":["beclabuvir","beclabuvir hydrochloride","beclabuvir HCl","BMS-791325","BMS 791325"],"offLabel":[],"synonyms":["beclabuvir","beclabuvir hydrochloride","beclabuvir HCl","BMS-791325","BMS 791325"],"timeline":[{"date":"2016-12-19","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Bristol-Myers Squibb)"}],"aiSummary":"Beclabuvir, marketed by Bristol-Myers Squibb, is a chronic hepatitis C treatment that blocks the potassium voltage-gated channel subfamily H member 2 to inhibit viral replication. Its key strength lies in its unique mechanism of action, distinguishing it from other direct-acting antivirals in the same class. The primary risk is the competitive landscape, with multiple same-class drugs already on the market, including ribavirin, telaprevir, boceprevir, simeprevir, and daclatasvir, all of which have varying patent protections and FDA approvals.","ecosystem":[{"indication":"Chronic hepatitis C","otherDrugs":[{"name":"boceprevir","slug":"boceprevir","company":"Merck Sharp Dohme"},{"name":"daclatasvir","slug":"daclatasvir","company":"Bristol Myers Squibb"},{"name":"dasabuvir","slug":"dasabuvir","company":"Abbvie Inc"},{"name":"elbasvir","slug":"elbasvir","company":"Merck Sharp Dohme"}],"globalPrevalence":58000000}],"mechanism":{"target":"Potassium voltage-gated channel subfamily H member 2","targets":[{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Beclabuvir acts as a selective inhibitor of the potassium voltage-gated channel subfamily H member 2, which is a critical component of the hepatitis C virus replication complex. By blocking this channel, beclabuvir disrupts the virus's ability to replicate and cause disease."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5215","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BECLABUVIR","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BECLABUVIR","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:54:50.013579","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:17:04.068136+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ribavirin","drugSlug":"ribavirin","fdaApproval":"1985-12-31","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telaprevir","drugSlug":"telaprevir","fdaApproval":"2011-05-23","patentExpiry":"May 30, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"boceprevir","drugSlug":"boceprevir","fdaApproval":"2011-05-13","patentExpiry":"Nov 11, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"simeprevir","drugSlug":"simeprevir","fdaApproval":"2013-11-22","patentExpiry":"Sep 5, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"daclatasvir","drugSlug":"daclatasvir","fdaApproval":"2015-07-24","patentExpiry":"Jun 13, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"sofosbuvir","drugSlug":"sofosbuvir","fdaApproval":"2013-12-06","patentExpiry":"Sep 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dasabuvir","drugSlug":"dasabuvir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"elbasvir","drugSlug":"elbasvir","fdaApproval":"2016-01-28","relationship":"same-class"},{"drugName":"grazoprevir","drugSlug":"grazoprevir","fdaApproval":"2016-01-28","relationship":"same-class"},{"drugName":"ledipasvir","drugSlug":"ledipasvir","fdaApproval":"2014-10-10","relationship":"same-class"},{"drugName":"ombitasvir","drugSlug":"ombitasvir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"paritaprevir","drugSlug":"paritaprevir","fdaApproval":"2014-12-19","relationship":"same-class"},{"drugName":"ritonavir","drugSlug":"ritonavir","fdaApproval":"1996-03-01","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"beclabuvir","indications":{"approved":[{"name":"Chronic hepatitis C","source":"DrugCentral","snomedId":128302006,"regulator":"FDA","usPrevalence":2400000,"globalPrevalence":58000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2024"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"ribavirin","brandName":"ribavirin","genericName":"ribavirin","approvalYear":"1985","relationship":"same-class"},{"drugId":"telaprevir","brandName":"telaprevir","genericName":"telaprevir","approvalYear":"2011","relationship":"same-class"},{"drugId":"boceprevir","brandName":"boceprevir","genericName":"boceprevir","approvalYear":"2011","relationship":"same-class"},{"drugId":"simeprevir","brandName":"simeprevir","genericName":"simeprevir","approvalYear":"2013","relationship":"same-class"},{"drugId":"daclatasvir","brandName":"daclatasvir","genericName":"daclatasvir","approvalYear":"2015","relationship":"same-class"},{"drugId":"sofosbuvir","brandName":"sofosbuvir","genericName":"sofosbuvir","approvalYear":"2013","relationship":"same-class"},{"drugId":"dasabuvir","brandName":"dasabuvir","genericName":"dasabuvir","approvalYear":"2014","relationship":"same-class"},{"drugId":"elbasvir","brandName":"elbasvir","genericName":"elbasvir","approvalYear":"2016","relationship":"same-class"},{"drugId":"grazoprevir","brandName":"grazoprevir","genericName":"grazoprevir","approvalYear":"2016","relationship":"same-class"},{"drugId":"ledipasvir","brandName":"ledipasvir","genericName":"ledipasvir","approvalYear":"2014","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT03071133","phase":"","title":"Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-01-01","conditions":["Hepatitis C"],"enrollment":344,"completionDate":"2019-01-08"},{"nctId":"NCT02124044","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2014-02","conditions":["HIV-HCV"],"enrollment":30,"completionDate":"2016-11"},{"nctId":"NCT02292966","phase":"PHASE4","title":"Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"2015-07","conditions":["Hepatitis C, Chronic"],"enrollment":0,"completionDate":"2016-06"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"MYW1X5CO9S","INN_ID":"9899","UMLSCUI":"C4045497","chemblId":"CHEMBL4739903","ChEMBL_ID":"CHEMBL3126842","KEGG_DRUG":"D10611","DRUGBANK_ID":"DB12225","PUBCHEM_CID":"56934415","SECONDARY_CAS_RN":"958002-36-3","MESH_SUPPLEMENTAL_RECORD_UI":"C587012"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Bristol-Myers Squibb","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"5.38 hours","clearance":"1.33 mL/min/kg","fractionUnbound":"0.01%","volumeOfDistribution":"0.5 L/kg"},"publicationCount":56,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AP58","allCodes":["J05AP58"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"BECLABUVIR","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:17:04.068136+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}